|
- Phase 3 studies survodutide obesity and overweight | Boehringer Ingelheim
SYNCHRONIZE-1 and SYNCHRONIZE-2 are global Phase III studies of survodutide (BI 456906) in people living with obesity and overweight without and with type 2 diabetes, respectively A third study, SYNCHRONIZE-CVOT, is a global, long-term cardiovascular safety study of survodutide in people living with obesity and overweight with cardiovascular disease, chronic kidney disease or with risk factors
- Survodutide for the Treatment of Obesity: Rationale and Design of the . . .
SYNCHRONIZE-CVOT is the first trial that will determine the CV safety and efficacy of survodutide in people with obesity and increased CV risk (A Study to Test the Effect of Survodutide [BI 456906] on Cardiovascular Safety in People With Overweight or Obesity [SYNCHRONIZE–CVOT]; NCT06077864)
- Survodutide for the Treatment of Obesity: Rationale and Design of the . . .
SYNCHRONIZE-CVOT is the first trial that will determine the CV safety and efficacy of survodutide in people with obesity and increased CV risk (A Study to Test the Effect of Survodutide [BI 456906] on Cardiovascular Safety in People With Overweight or Obesity [SYNCHRONIZE-CVOT]; NCT06077864)
- Survodutide for treatment of obesity: rationale and design of two . . .
The SYNCHRONIZE-CVOT trial is evaluating the cardiovascular safety of survodutide over a longer period in nearly 5000 participants with obesity and increased cardiovascular risk
- Home - ClinicalTrials. gov
We would like to show you a description here but the site won’t allow us
- Boehringer moves obesity therapy into phase 3 - pharmaphorum
Boehringer Ingelheim and Zealand Pharma have kicked off three phase 3 trials of obesity drug candidate survodutide, in patients with and without diabetes, in the hope of breaking into a market
- Survodutide for the Treatment of Obesity: Rationale and Design of the . . .
SYNCHRONIZE-CVOT is the first trial that will determine the CV safety and efficacy of survodutide in people with obesity and increased CV risk (A Study to Test the Effect of Survodutide [BI 456906] on Cardiovascular Safety in People With Overweight or Obesity [SYNCHRONIZE–CVOT]; NCT06077864)
- Survodutide Phase III study weight loss | Boehringer Ingelheim
Boehringer Ingelheim today announced it will advance survodutide, its glucagon GLP-1 receptor dual agonist, into three registrational Phase III studies for people living with overweight or obesity This decision was based on recently presented data from a Phase II dose finding study in people living with overweight or obesity The study demonstrated up to 19 percent weight loss after 46 weeks
|
|
|